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Development and validation of HPLC and CE methods 
for simultaneous determination of amlodipine and atorvastatin 
in the presence of their acidic degradation products in tablets
Two methods were developed for separation and quantita-
tion of amlodipine (AML) and atorvastatin (ATV) in the 
presence of their acidic degradation products. The first 
method was a simple isocratic RP-HPLC method while the 
second was capillary electrophoresis (CE). Degradation 
products were obtained by acidic hydrolysis of the two 
drugs and their structures were elucidated for the first time 
by IR and MS spectra. Degradation products did not inter-
fere with the determination of either drug and the assays 
were therefore stability-indicating. The linearity of the pro-
posed methods was established over the ranges 1–50 μg 
mL–1 for AML and ATV in the HPLC method and in the 
range of 3–50 and 4–50 μg mL–1 for AML and ATV, respec-
tively, in the CE method. The proposed methods were vali-
dated according to ICH guidelines. The methods were suc-
cessfully applied to estimation of AML and ATV in 
combined tablets.
Keywords: atorvastatin, amlodipine, capillary zone electro-
phoresis, HPLC, stability, acidic degradation
Amlodipine [AML, 3-O-ethyl-5-O-methyl-2-(2-aminoethoxymethyl)-4-(2-chlorophenyl) -
6-methyl-1,4-dihydropyridine-3,5-dicarboxylate] (1) is a dihydropyridine calcium channel 
blocker, used for the management of hypertension and angina (2) (Fig. 1a). Atorvastatin 
{ATV, [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1–methylethyl)-3-phenyl-4-[(phenyl-
ami no)carbonyl]-1H-pyrrole-1-heptanoic acid} (1) is an HMG-CoA reductase inhibitor used 
to reduce LDL-cholesterol and triglycerides (2) (Fig. 1b). Caduet® tablets, launched by Pfizer 
Ltd. for simultaneous treatment of hypertension and dyslipidaemia, contain both AML 
and ATV.
AML and ATV are both official in British Pharmacopoeia (3) and United States Pharmaco-
peia (4) and different methods were reported for the determination of both drugs in differ-
ent dosage forms (5–12). Also, different methods have been applied for simultaneous esti-
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mation of AML and ATV in their binary mixtures (13–21). Stability indicating HPLC 
(22–24) and CE (25) have been used for the analysis of such a mixture. However, they nei-
ther isolated nor characterized the possible degradation products of the two drugs. The 
acidic degradation products of the two drugs were prepared, isolated and their structures 
were elucidated for the first time using MS and IR spectra in our previous work (26) (Fig. 
1), then full (PLS) and full (Ann) methods were applied for determination of the two 
drugs in the presence of these degradation products.
Fig. 1. Structural formulae of: a) amlodipine (AML), b) atorvastatin (ATV), c) AMdeg, d) ATdeg1 and 
e) ATdeg2 (aniline).
Table I. Separation parameters for HPLC and CE method
HPLC CE 
AML ATV AML ATV
tR (min) 3.97 6.52 tR (min) 3.84 6.28
Ta 0.97 1.03 Ta 1.01 0.97
Rsb 2.82 2.02 Rsd 21.38 21.42
TPM (m–1)c 5776 15904 TPM c (m–1) 213320 233286
HETP (mm) 173 63
k′ a 5.06 9.13
α b 1.36 1.15
a Tailing factor and capacity factor determined for individual peaks.
b  Chromatographic resolution and selectivity factor are determined between AML and AMdeg peaks and between 
ATV and ATdeg1 peaks.
c Efficiency expressed as the number of theoretical plates (N) per meter for AML and ATV peaks.
d Resolution factor determined between AML and ATdeg2 peaks and between ATV and ATdeg2 peaks.
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This manuscript aims to develop and validate stability indicating HPLC and CE 
methods for the simultaneous determination of AML and ATV in the presence of their 




Pure amlodipine besylate was kindly supplied by Al-Hekma Pharmaceutical Com-
pany, Egypt; its purity was certified to be 99.89 ± 0.69 %. Pure atorvastatin calcium was 
kindly supplied by the Al-Delta Pharmaceutical Company, Egypt; its purity was certified 
to be 99.79 ± 0.46 %. Caduet® 5 mg/10 mg tablets and Caduet® 10 mg/10 mg tablets 10 mg 
ATV and 5 and 10 mg AML, resp., were manufactured by Pfizer Ltd., Egypt. They were 
procured from the local market. Acetic acid, chloroform, hydrochloric acid, methanol, 
sodium hydroxide and toluene, all of analytical grade, were purchased from El-nASR 
Pharmaceutical Chemicals Co., Egypt. Acetonitrile, methanol and sodium tetraborate 
decahydrate were purchased from Sigma-Aldrich, Germany.
Instruments and conditions
HPLC, CE and GC instrumental setup comprised products of Agilent/Agilent Techno-
logies (USA, Germany)
HPLC. – All analyses were performed in an air-conditioned laboratory (18 ± 2 °C). An 
Agilent 1100 series liquid chromatograph consisting also of a dual pneumatic pumping 
system (model G1310A), an ultra-violet variable wavelength detector (model G1314A) and 
Rheodyne injector (model 7725 I) equipped with 20-μL injector loop (Agilent, USA) was 
used. Agilent zorbax® ODS column (5 µm, 4.6 x 250 mm), flow rate of 1.0 mL min–1 and UV 
detection were performed at 254.0 nm. An Agilent 7100 CE system, with a diode array 
detector (Agilent Technologies) was controlled by Chemstation software.
The mobile phase was prepared by mixing acetonitrile/methanol/phosphate buffer 
pH = 3.0 (45:30:25, V/V/V); pH was adjusted to 2.5 ± 0.1 with orthophosphoric acid. The mobile 
phase was degassed by ultrasonic vibrations for 30 min prior to use.
CE. – Separation was carried out at 18 ± 2 °C using a voltage of 15 kV (positive polarity) 
and detection at 200.0 nm. Peak purity was assessed using DAD. Bare fused silica capillaries 
used (Agilent Technologies) were of 50 µm id, 325 µm od, with a total/effective length of 
48.5/40.0 cm.
Preconditioning of the capillary before each run was carried out by flushing with 
0.1 mol L–1 NaOH, MilliQ water and finally with a background electrolyte (BGE) for 3 min 
each. Post-conditioning was carried out by flushing with MilliQ water for 5 min. Samples 
were injected hydrodynamically at 5 kPa for 5 s and 50 mmol L–1 borate buffer at pH 8.0 
was used as the BGE.
TLC plates 20 x 20 cm (Sigma-Aldrich, Germany) were coated with a 0.2-mm silica gel 
60 F254 layer. The sample was applied to the plates using micro-droppers and a UV lamp 
at 254 nm was used for visualization of the spots.
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The gas chromatograph coupled to a mass spectrophotometer was Shimadzu Qp-2010 
(Japan) with a Shimadzu AOC-20i autosampler. A 30 m, HP-5 MS column [(5 %-phenyl)-
methylpolysiloxane] was employed for separation, with a 0.253-mm i.d. and 0.50-µm film 
thickness (Agilent). The IR spectrophotometer was Shimadzu 435 and sampling was un-
dertaken as potassium bromide discs and naCl plates.
Preparation and separation of acidic degradation products (26)
Amlodipine degradation product. – Fifty milliliters of 1.0 mol L–1 HCl were added to 
50.0 mg AML in a conical flask, the solution was refluxed for 2 h and then cooled. NaOH 
(1.0 mol L–1) was added to the degraded solution up to pH 7.0 and the solution was tested 
for complete degradation by TLC using chloroform/methanol/acetic acid (86.2:11.5:2.3, 
V/V/V) as developing solvent. The solution was then evaporated slowly in a rotary evapora-
tor to dryness. The degradation product was extracted with methanol and then methanol 
was evaporated. The extraction was repeated three times to ensure complete extraction of 
the degradation product. Purity of the degradation product was tested by dissolving a 
small portion in methanol, applying it onto TLC plates and developing using the previ-
ously mentioned solvent system and then visualizing under a UV lamp. The structure of 
the isolated degradation product was elucidated using mass spectrometry and IR (26) 
(Figs. S1 and S2). The mass spectrum of the AML degradation product showed a peak at 
m/z 367 corresponding to AMdeg and the IR spectra showed a shift of the carbonyl band 
from 1682 to 1579 cm–1, indicating formation of an acid (26).
Atorvastatin degradation products. – Fifty milligrams of ATV were dissolved in the small-
est volume of methanol in a conical flask, then 50.0 mL of 6.0 mol L–1 HCl solution was 
added, the solution was refluxed for 3 h and then cooled. NaOH (6.0 mol L–1) was added to 
the degraded solution up to pH 7.0 and the solution was tested for complete degradation by 
TLC using toluene/methanol (70:30, V/V) as a developing solvent (27). The solution was then 
evaporated slowly in a rotary evaporator to dryness to obtain the first degradation product 
(ATdeg1). The collected evaporated liquid was heated at 100 °C to get rid of solvents and the 
second degradation product (ATdeg2) was obtained. The degradation product (ATdeg) was 
extracted from solid naCl (produced from HCl neutralization by naOH) with methanol and 
then methanol was evaporated. The extraction was repeated three times to guarantee com-
pleteness. Purity of the degradation product was tested by dissolving a small portion in 
methanol, applying it onto TLC plates and developing using the previously mentioned sol-
vent system and then visualizing under a UV lamp. Structures of the isolated degradation 
products were elucidated using IR and mass spectrometry (26) (Figs. S3 and S4). The mass 
spectra showed peaks at m/z 483 and 93 corresponding to ATdeg1 and ATdeg2. The IR spectra 
showed disappearance of the nH band at 3421 cm–1 and appearance of a forked peak at 3431 
and 3356 cm–1 corresponding to the nH2 group in ATdeg2 (26).
Standard solutions
Standard stock solutions of AML and ATV were 1 mg mL–1 in methanol. Standard 
working solutions of AML, ATV, amlodipine degradation product (AMdeg), atorvastatin 
degradation products (ATdeg1 and ATdeg2, namely, aniline) were 100 μg mL–1 in methanol.
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Procedures
Calibration curves. – For HPLC, solutions of AML and ATV of 1.0–50.0 μg mL–1 were 
prepared. The volume of 20 μL of each solution was injected in triplicate into the liquid 
chromatograph under the previously mentioned chromatographic conditions. The average 
peak area obtained for each AML and ATV concentration was plotted versus concentration, 
and regression equations were computed.
For CE solutions of 3.0–50.0 and 4.0–50.0 μg mL–1 of AML and ATV, respectively, were 
prepared in BGE. Samples were injected hydrodynamically under the previously mentioned 
electrophoretic conditions. Migration time-corrected peak areas were plotted versus AML 
and ATV concentrations and the corresponding regression equations were calculated.
Validation of HPLC and CE methods
Validation of the proposed methods was performed with respect to specificity, accu-
racy, precision, LOD, LOQ, linearity and range, robustness and stability according to the 
ICH guidelines (28).
Specificity. – Specificity of the methods was achieved with analyses of different labora-
tory prepared mixtures of AML and ATV spiked with different levels of degradation prod-
ucts, ranging from 10–70 % degradation.
Accuracy. – Accuracy was confirmed by applying the proposed methods to determina-
tion of three concentrations (8, 12 and 16 μg mL–1) of AML and ATV standards (n = 3).
Precision. – Repeatability and intermediate precision were assessed using three con-
centrations (10, 20 and 30 μg mL–1) of standard AML and ATV solutions (n = 3).
LOD and LOQ. – According to the ICH recommendations (28), the approach based on 
the residual standard deviation of a regression line and the slope was applied to calculate 
the detection and quantitation limits.
Linearity and range. – Linearity of the methods was evaluated by analyzing six concen-
trations of AML and ATV (n = 3). The assays were performed according to the experimen-
tal conditions previously mentioned. A linear relationship was established by plotting the 
peak area (for HPLC) or migration time-corrected peak area (for CE) against the drug 
concentration.
Robustness. – Robustness of the proposed methods was evaluated by the reliability of 
the analysis with respect to small variations in the experimental conditions. These param-
eters included the portion of acetonitrile (45 ± 5 %), acidity of mobile phase (pH 2.5 ± 0.3), 
flow rate (1.0 ± 0.1 mL min–1) and detection wavelength (254.0 ± 2.0 nm) for the HPLC 
method, while the parameters for the CE method were acidity of the BGE (pH 8.0 ± 0.3) and 
applied voltage (15 ± 1 kV). Three concentrations (10, 20 and 30 µg mL–1) of standard AML 
and ATV (n = 3) were analyzed and only one parameter was changed at a time.
Application of HPLC and CE for determination of AML and ATV in Caduet® tablets
Ten tablets of both Caduet® 5/10 mg and 10/10 mg were accurately weighed and finely 
powdered. The amount of the powder equivalent to 2 mg ATV was accurately weighed and 
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dissolved in methanol by shaking in an ultrasonic bath for about 30 min. The solution was 
filtered and transferred quantitatively into four separate 100-mL volumetric flasks. The 
volume was then completed to the mark with the mobile phase or BGE. Suitable aliquot 
was transferred into four 10-mL measuring flask, the volume was completed with the 
mobile phase or BGE and analyzed as described above.
RESULTS AnD DISCUSSIOn
Methods development and optimization
HPLC. – Different columns, such as Zorbax Eclipse C8 (5 μm, 4.6 x 150 mm) and Agi-
lent zorbax® ODS (5 μm, 4.6 x 250 mm) were investigated. zorbax® ODS produced suffi-
cient separation of AML from ATV, with different retention times and excellent resolution 
Table II. Validation of the proposed HPLC and CE methods for simultaneous determination of AML and ATV 
in the presence of acidic degradants
Parameter
HPLC method CE method
AML ATV AML ATV
Specificity (recovery ± SD, %)a 100.9 ± 1.0 99.9 ± 1.1 99.7 ± 1.0 100.4 ± 0.7 
Accuracy (recovery, %)b 100.2 99.6 100.5 100.3 
Precision, RSD (%)
– Repeatabilityc 0.9 0.9 0.8 0.8 
– Intermediate precisiond 1.0 1.2 1.0 1.0 
LOD (μg mL–1)e 0.31 0.29 0.92 1.21
LOQ (μg mL–1)e 1.00 0.98 3.06 4.03
Regression line 
– Slope ± RSD (%) 69.2673 ± 1.2 59.289 ± 1.2 0.1687 ± 1.1 0.2220 ± 1.5
– Intercept ± RSD (%) 62.8858 ± 1.7 –14.9302 ± 2.0 –0.3046 ± 1.3 –0.7732 ± 1.4
– Correlation coefficient (R) 0.9999 0.9998 0.9996 0.9997
Linearity range (μg mL–1) 1.0–50.0 1.0–50.0 3.0–50.0 4.0–50.0
Robustness (recovery ± SD, %)f 100.2 ± 0.8 % 100.3 ± 0.9 % 100.1 ± 0.8 % 100.1 ± 0.7 % 
a  Mean ± SD (n = 3) of laboratory prepared mixtures of AML and ATV spiked with different levels of degradation 
products, ranging from 10–70 % degradation.
b  Mean (n = 3) of three concentrations (8, 12 and 16 μg mL–1) for AML and ATV.
c  Intraday (n = 3), three concentrations (10, 20 and 30 μg mL–1) for AML and ATV repeated three times within the 
day.
d  Interday (n = 3), three concentrations (10, 20 and 30 μg mL–1) for AML and ATV repeated three times in three days.








 (σ is the residual stan-
dard deviation, S is the slope).
f  Robustness (n = 3), three concentrations (10, 20 and 30 μg mL–1) for AML and ATV.
485
S. A. Hassan et al.: Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and ator-
vastatin in the presence of their acidic degradation products in tablets, Acta Pharm. 66 (2016) 479–490.
 
Fig. 2. HPLC chromatogram of: a) Caduet® 5/10 tablets, amlodipine (AML) and atorvastatin (ATV), 
b) synthetic mixture of the two drugs together with the degradation products,  ATdeg2 (aniline), AML, 
AMdeg, ATV and ATdeg1.
from the degradation products. Different mobile phases were investigated. Different ratios 
of acetonitrile or methanol with water were tested [with organic solvent from 40 to 80 %, 
no separation was observed, and with different ratios of organic modifiers and water 
(equal volumes of methanol and acetonitrile with different % of water) no resolution was 
noted]. Phosphate buffer was then introduced in different percentages instead of water and 
the pH was adjusted from 2.5 to 8.0 using orthophosphoric acid or triethylamine. The 
mobile phase of choice was found to be acetonitrile/methanol/phosphate buffer, (45:30:25, 
V/V/V); pH was adjusted to 2.5 ± 0.1 with orthophosphoric acid. UV detection was tested 
at 238.0 and 254.0 nm (Fig. S5) and the highest sensitivity was obtained using the latter 
(Fig. 2 and Table I).
CE. – The buffer type, pH and applied voltage are the key factors for optimization of 
separation. As pKa of AML is 8.6 while pKa of ATV is 4.46 and the degradation products 
were of acidic nature, alkaline pH would be a good choice for applying electric charge to 
the compounds. Phosphate and borate buffers were tested at pH 8.0 and 10.0. Best results 
concerning migration time, resolution, peak shape, peak height, baseline noise, and the 
electric current produced were achieved by borate buffer pH = 8.0. Voltages of 15 and 20 kV 
were applied and the best separation and migration times were achieved with 15 kV. The 
detection was tested at 238.0, 244.0 and 200.0 nm (Fig. S5), and the best sensitivity was 
obtained at 200.0 nm (Fig. 3 and Table I).
Method validation
The results of method validation are summarized in Table II.
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Linearity and range. – Concentration ranges were found to be linear in the range of 1–50 
μg mL–1 for AML and ATV in the HPLC method and 3–50 and 4–50 μg mL–1 for AML and 
ATV, respectively, in the CE method.
Specificity. – Satisfactory recoveries were obtained ranging from 99.4–101.8 % and 
98.9–101.8 % for AML and ATV, respectively, in the HPLC method and 98.6–101.6 % and 
99.3–101.2 % for AML and ATV, respectively, in the CE method. These results demon-
strated that the assay results were unaffected by the presence of the degradation products 
(see Table SI). Specificity was also assessed by observing the possible interferences from 
excipients in the analysis of tablets. The obtained chromatograms and electropherograms 
did not show any additional peaks when compared to those of the synthetic mixtures (see 
Figs. 2 and 3).
Purity of the peaks was evaluated by DAD in the CE method with the purity factor of 
999.876 and 999.583 for AML and ATV, respectively, when their laboratory prepared mix-
ture was spiked with the degradation products (see Figs. 3, S6 and S7).
Accuracy. – Satisfactory mean percentage recoveries were obtained, 100.2 and 99.6 % 
for AML and ATV, respectively, in the HPLC method, and 100.5 and 100.3 % for AML and 
Fig. 3. Electropherogram of: a) Caduet® 5/10 tablets, amlodipine (AML) and atorvastatin (ATV), 
b) synthetic mixture of the two drugs together with the degradation products, AML, ATdeg2 (aniline), 
ATV, AMdeg and ATdeg1.
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ATV, respectively, in the CE method (Table II). The accuracy was confirmed using the 
standard addition technique (Table III).
Precision. – In the HPLC method, repeatability RSD was 0.9 % for both AML and ATV. 
In the CE method, it was 0.8 % for both AML and ATV. In HPLC, intermediate RSD was 
1.0 and 1.2 % for AML and ATV, respectively, and it was 1.0 % for both in the CE method.
The RSD being below 1.5 % for both methods indicated reasonable repeatability and inter-
mediate precision.
LOD and LOQ. – In the HPLC method, the LOD for AML and ATV was 0.31 and 
0.29 μg mL–1, respectively, and it was 0.92 and 1.21 μg mL–1 for AML and ATV, respectively, 
in the CE method. The LOQ in the HPLC method was 1.00 and 0.98 μg mL–1 for AML and 
ATV, respectively, and it was 3.06 and 4.03 μg mL–1 for AML and ATV, respectively, in CE 
method.
Robustness. – Small changes, as defined in the Experimental part, did not affect the 
recovery of the drugs or the system suitability parameters of the proposed methods. Re-
coveries ranged from 100.1 to 100.3 % and RSD below 1 % indicating that the methods were 
robust enough regarding these changes (Tables SII and SIII). (RSD was 0.8 and 0.9 % for 
AML and ATV, respectively, in HPLC, and 0.8 % for both AML and ATV in the CE method).


















AML   4.97 ± 0.68   5.02 ± 0.87 10
5.00 99.4 ± 0.9 101.6 ± 0.9
10.00 100.4 ± 0.6 99.9 ± 0.6
15.00 99.2 ± 1.0 100.2 ± 1.1
ATV   9.98 ± 0.57 10.00 ± 1.19 20
10.00 99.2 ± 0.8 99.1 ± 0.9
20.00 99.3 ± 1.1 98.8 ± 0.8
30.00 101.0 ± 0.7 100.1 ± 1.0
Caduet®
10/10
AML 10.08 ± 0.59 10.08 ± 0.41 20
10.00 99.6 ± 1.0 99.7 ± 0.7
20.00 100.9 ± 1.2 101.0 ± 0.9
30.00 98.7 ± 0.9 101.4 ± 0.8
ATV   9.98 ± 0.72 10.05 ± 0.89 20
10.00 99.6 ± 1.1 99.7 ± 1.0
20.00 99.6 ± 0.6 101.0 ± 0.9
30.00 100.9 ± 1.0 100.6 ± 0.5
a Average ± SD (n = 3).
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Analyses of tablets
Accuracy of the methods was further assured by the comparison of the results of the 
assay of the studied drugs in the pharmaceutical formulations with those of a reported 
HPLC method (23). Statistical analysis of the results using Student’s t-test and variance 
ratio F-test revealed no significant differences between the performance of the new meth-
ods and the literature method (Table IV).
Table IV. Statistical analysis of the results obtained by the proposed methods and the reported HPLC method 
for the analysis of AML and ATV in Caduet® 5/10 tablets
Value
HPLC method CE method Reported HPLC method
 
(ref. 23)a
AML ATV AML ATV AML ATV
Mean (%) 100.1 99.8 100.6 100.3 99.9 100.4
RSD (%) 0.9 0.6 0.7 1.0 1.2 1.0
n 6 6 6 6 6 6
Student’s t-test
(2.228) b 0.301 1.194 1.255 0.153 – –
F-value
(5.05) b 1.635 2.937 3.350 1.038 – –
a   Perfectsil® Target ODS-3 column using acetonitrile: 0.025 mol L–1 naH2PO4 buffer pH 4.5 (55:45, V/V) at 1 mL min–1 
and UV detection at 237 nm.
b Values in the parentheses are the corresponding theoretical values of t and F at p = 0.05.
COnCLUSIOnS
Acidic degradation products of AML and ATV were isolated and their structures were 
elucidated. The main criteria for the development of a successful separation method for 
determination of AML and ATV in tablets were that the method should be able to deter-
mine drugs in a single run and should be accurate, precise, robust, free of interference from 
excipients or degradation products and simple enough for use in the quality control labo-
ratories. The proposed HPLC and CE methods were selective, precise, accurate and simple-
Degradation products did not interfere with the determination of drugs and therefore the 
assay was considered stability-indicating. The proposed methods can be used for the rou-
tine analysis of AML and ATV in pharmaceutical formulations in the presence of their 
acidic degradation products. Unlike the other stability indicating methods, the degradation 
products were isolated and identified in this work. The CE method showed better resolution 
and chromatographic parameters than the HPLC method. In addition, CE shows better 
environmental acceptability and is considered a green method, since no harmful organic 
solvents are used. The known disadvantage of CE is its being of lower sensitivity than 
HPLC, but this was not of great significance in this work as the application was in a phar-
maceutical dosage form.
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